CD22 and acute lymphoblastic leukemia: A phase 1/2 study of CD19/CD22 bispecific CAR T-cells in MRD-positive BCP-ALL, conducted in newly diagnosed patients after induction, reported a 100% response rate with 88% MRD-negative CR, suggesting potential for chemo-free consolidation in frontline settings [21].